Lyons Kelly E, Pahwa Rajesh
Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA.
J Neurosurg. 2006 Apr;104(4):502-5. doi: 10.3171/jns.2006.104.4.502.
The aim of this study was to assess the long-term effects of bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) on sleep, daytime sleepiness, and early morning dystonia and to evaluate the relationship between total sleep time and motor function.
Patients who had undergone bilateral STN DBS and a follow-up evaluation of 6 months (89 patients), 12 months (83 patients), and 24 months (43 patients) were included in this study. The patients were preoperatively assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) in the medication-on and -off conditions, and they completed patient diaries. A subset of patients also completed the Epworth Sleepiness Scale. These assessments were repeated postoperatively with stimulation. The UPDRS activities of daily living (ADL) and motor scores as well as total sleep hours were significantly improved at 6, 12, and 24 months poststimulation and with no medication compared with baseline values. Increased sleep time was significantly correlated with improvements in bradykinesia but not with tremor or rigidity. Patient-reported sleep problems and early morning dystonia were reduced after STN DBS. Antiparkinsonian medications were significantly reduced after STN DBS; however, there were no changes in excessive daytime sleepiness 6, 12, or 24 months after surgery.
Bilateral STN DBS increased total sleep time and reduced patient-reported sleep problems and early morning dystonia for up to 24 months posttreatment. These changes in sleep were related to improvements in functioning, specifically those affected by bradykinesia. Despite significant reductions in antiparkinsonian medications, STN DBS did not reduce excessive daytime sleepiness.
本研究旨在评估丘脑底核(STN)双侧深部脑刺激(DBS)治疗帕金森病(PD)对睡眠、日间嗜睡和清晨肌张力障碍的长期影响,并评估总睡眠时间与运动功能之间的关系。
本研究纳入了接受双侧STN DBS并进行了6个月(89例患者)、12个月(83例患者)和24个月(43例患者)随访评估的患者。术前在服药和未服药状态下使用统一帕金森病评定量表(UPDRS)对患者进行评估,并让他们完成患者日记。一部分患者还完成了爱泼华嗜睡量表。术后在刺激状态下重复这些评估。与基线值相比,刺激后6个月、12个月和24个月以及不服药时,UPDRS日常生活活动(ADL)和运动评分以及总睡眠时间均有显著改善。睡眠时间增加与运动迟缓的改善显著相关,但与震颤或强直无关。STN DBS后患者报告的睡眠问题和清晨肌张力障碍有所减少。STN DBS后抗帕金森药物显著减少;然而,术后6个月、12个月或24个月日间过度嗜睡没有变化。
双侧STN DBS可增加总睡眠时间,并在治疗后长达24个月内减少患者报告的睡眠问题和清晨肌张力障碍。这些睡眠变化与功能改善有关,特别是与受运动迟缓影响的功能改善有关。尽管抗帕金森药物显著减少,但STN DBS并未减少日间过度嗜睡。